Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.